tbuckley/cabot-search huggingface dataset:
Insight Into Opacity: Clues to Cataract Formation
Authors: M J Friedrich
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutations In The Zinc Finger Domain Of Human and Mouse KLF1 Cause Congenital Dyserythropoietic Anemia (CDA) Via Promiscuous DNA Binding and Ectopic Target Gene Expression
Authors: Kevin R Gillinder, Mathieu Lajoie, Melissa Ilsley, Michael R Tallack, Graham Magor, Michael Landsberg, Timothy L Bailey, Andrew C Perkins
Journal: Blood (2013)
The new impact factor and immediacy index of World Psychiatry
Authors: MARIO LUCIANO
Journal: World Psychiatry (2012)

The new impact factor of World Psychiatry, based on citations in the year 2011 to papers published in the journal in the years 2009 and 2010, is 6.233. The impact factor of the journal was 3.896 in 2009, 4.375 in 2010, and 5.562 last year. The journal is in the top 10 of psychiatric journals and is preceded only by the American Journal of Psychiatry, the Archives of General Psychiatry and the British Journal of Psychiatry among journals of general psychiatry. The papers that received the highest number of citations during the period considered in the calculation of the new impact factor are the Special Articles by De Hert et al 1 on the metabolic syndrome in people with schizophrenia, by A.C. McFarlane 2 on the long-term costs of traumatic stress, by D. Cicchetti 3 on resilience, and by A. Bateman and P. Fonagy 4 on mentalization based treatment for borderline personality disorder; the WPA guidance papers on steps, obstacles and mistakes to avoid in the implementation of community mental health care 5,6 and on how to combat stigmatization of psychiatry and psychiatrists 7; the Forums “Are psychiatrists an endangered species?” 8,9, “Pathophysiology of depression: do we have any solid evidence of interest to clinicians?” 10, and “Problematic Internet use — research evidence and open issues” 11; and the Research Reports by J. Angst et al 12 on hypomania from a transcultural perspective, by O. Gureje et al 13 on the Nigerian Survey on Mental Health and Wellbeing, and by V. Patel et al 14 on reducing the treatment gap for mental disorders. The new immediacy index of the journal, based on citations in the year 2011 to papers published in the same year, is 2.556. It was 0.950 last year. The journal is in the top 3 of psychiatric journals according to this measure, preceded only by Molecular Psychiatry (3.676) and the American Journal of Psychiatry (3.583). The immediacy index of the Archives of General Psychiatry is 2.202. This immediacy index of the journal is mostly due to the high number of citations received by papers related to the development of the ICD-11 15,16,17,18,19 and by other WPA guidance papers, educational modules and recommendations 20,21,22,23,24,25. The journal editorial staff is grateful to the authors, the referees and the WPA task forces who made these accomplishments possible.
Abstract 17341: Use and Effectiveness of Drug-Eluting versus Bare Metal Stents in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: Insights from the National VA Clinical Assessment, Reporting and Tracking (CART) Program
Authors: Thomas T Tsai, Thomas M Maddox, Brahmajee K Nallamothu, Maggie A Stanislawski, Jill C Adams, Tamara L Box, P. Michael Ho, Sunil V Rao, Ivan P Casserly, John S Rumsfeld, Emmanouil S Brilakis
Journal: Circulation (2011)

Background: Little is known about the use and outcomes of drug eluting stents (DES) versus bare metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary interventions (PCI). Methods: From the National VA CART program database of 59 catheterization laboratories, we identified all VA patients undergoing SVG PCI (n=2636). Based on a propensity score to receive a DES, we identified a matched cohort of 920 patients who received a DES to 920 patients who received a BMS (n=1840 total) during an index SVG PCI between October, 2004 and September, 2010. Kaplan-Meier analyses were performed to determine the association of DES vs BMS use and follow-up myocardial infarction, revascularization and death. Results: SVG PCI represented 7.3% of the total PCI volume (2636 of 36,256 patients). Of these, 1615 (61.2%) were treated with a DES and embolic protection devices were successfully used in 32.5% of patients. In the propensity matched cohort, the 2-year rate of MI was significantly lower among patients who received DES versus BMS (19% vs 23.9%, p=0.005) (Figures). However, the 2 year mortality and revascularization rates were not significantly different in the DES versus BMS groups respectively (9.2% vs 12.0%, p= 0.14 and 22.3% vs 20.6%, p=0.24). Conclusion: In a large national SVG-PCI registry, DES compared to BMS use was associated with lower rates of MI but similar revascularization and death rates.
Prenatal exposures and childhood cancer.
Authors: Frederica P. Perera, Manuela A. Orjuela, Kirsti A. Bocskay, Deliang Tang, Robin M. Whyatt, Mel Greaves, Anthony Ford, Dorothy P. Warburton
Journal: Cancer Research (2006)

SY03-02   Many lines of evidence suggest a role for  in utero  environmental exposures in childhood cancer, especially in childhood acute lymphocytic leukemia (ALL). For example, the chromosomal rearrangement t(12;21), commonly seen in childhood ALL, is detectable in the neonatal blood spots (Guthrie cards) of the cases (6). Although data are conflicting, there is epidemiologic evidence that maternal exposure in pregnancy to pesticides, vehicle exhaust emissions, benzene, environmental tobacco smoke (ETS) as well as polymorphisms in children9s genes that metabolize these xenobiotics (e.g., CYP1A1, GST-M1, -T1, -P1) are associated with childhood ALL (3;5)(4;8)(7). In addition to the NYC (NM) cohort, the populations were participants in a study of the effects of the World Trade Center (WTC) disaster, residents in Krakow, Poland, and residents in Tongliang, China. Mean adduct concentrations in both maternal and cord blood and the proportion of samples with detectable adducts increased across the populations [NM  in utero  exposure to PAHs may disproportionately increase carcinogenic risk. Heightened fetal susceptibility could result from higher rate of cell proliferation and differentiation, greater absorption or retention of xenobiotics, and/or less efficient detoxification, DNA repair, or apoptotic mechanisms. Chromosomal aberrations are a validated intermediate marker for increased risk for cancer. Using fluorescence  in situ  hybridization (FISH) with whole chromosome painting probes for chromosomes 1–6, we have measured chromosomal aberrations in a representative subset of 60 newborns of the CCCEH NYC cohort (2). The frequency of stable chromosomal aberrations was significantly associated with exposure to PAHs (p= in utero  exposures, we are evaluating specific changes known to be directly pre-leukemogenic. The TEL-AML1 fusion product appears to be a necessary but not sufficient step for the development of childhood ALL (4;6)(6). The origin of these initial chromosomal translocations is not known but appears to be linked to prenatal exposures. We are currently analyzing cord blood samples from our cohort for TEL-AML1 in order to evaluate their possible relationship with prenatal exposures. These studies suggest that there is substantial transplacental exposure to carcinogens in the urban environment, that procarcinogenic genetic damage in the form of adducts and chromosomal aberrations results from prenatal exposures, and that the fetus is more susceptible to DNA damage than the mother. Further studies are ongoing to determine the persistence of chromosomal aberrations through early childhood and the relationship between prenatal exposures and specific pre-leukemogenic rearrangements in cord blood samples. Such molecular epidemiologic data can help inform us of the full range of carcinogenic risk from environmental exposures and thus contribute to the development of policies that will protect the young.
Endoscopic Retrograde Cholangiopancreatography: Technique, Diagnosis and Therapy
Authors: Jerome H. Siegel, J. Delmont, A. G. Harris
Journal: Annals of Internal Medicine (1992)

Part 1 Technique: introduction and development indications, contraindications, preparation endoscopic technique. Part 2 Diagnosis: radiologic - normal biliary system and variations and normal pancreatic duct and variations intrahepatic cholestasis extrahepatic cholestasis - obstructive jaundice periampullary findings - atlas of duodenoscopy advantages and limitations of endoscopic manometry of the sphincter of Oddi pancreatic disorders inflammatory, congenital, and malignant. Part 3 Therapeutic endoscopy: endoscopic sphincterotomy - stone extraction, lithtripsy, and stents and stones decompression techniques - nasobiliary catheters and endoprostheses cholangiopancreatoplasty - hydrostatic dilatation of strictures of the biliary tree and pacreas new horizions.
Abstract P252: Sarcopenic Obesity is Associated With a High Burden of Cardiovascular Disease
Authors: Jiantao Ma, Shih-Jen Hwang, Gearoid M McMahon, Gary C Curhan, Robert R McLean, Joanne M Murabito, Caroline S Fox
Journal: Circulation (2015)

Introduction: Sarcopenic obesity, characterized by low muscle mass in the setting of obesity, may be associated with more adverse metabolic outcomes relative to obesity alone. Studies that have examined sarcopenic obesity and cardiovascular disease are scarce. Hypothesis: We tested the hypothesis that sarcopenic obesity is associated with an increased burden of cardiovascular disease (CVD). Methods: We examined cross-sectional associations between sarcopenic obesity and CVD risk factors in the Framingham Heart Study Offspring and OMNI cohorts (n=1005; 46.4% women; mean age 69.8 years). Muscle mass was assessed using 24-hour urinary creatinine concentration (24h UC). We categorized participants into four groups by BMI (cut-point of 30 kg/m2) and median value of 24h UC (1069 mg/d in women and1673 mg/d in men). Participants had higher BMI and lower 24h UC were grouped into sarcopenic obesity. CVD risk factors were metabolic syndrome (METS), hypertension (HTN), type 2 diabetes (T2D), chronic kidney disease (C...
Endocarditis Following Septic Abortion With Special Reference to Sub-Acute Bacterial Endocarditis
Authors: Carl H. Fortune
Journal: Annals of Internal Medicine (1929)

Article1 March 1929Endocarditis Following Septic Abortion With Special Reference to Sub-Acute Bacterial EndocarditisCARL H. FORTUNE, A.B., M.D.CARL H. FORTUNE, A.B., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-2-9-912 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThat endocarditis, particularly sub-acute bacterial endocarditis, may be a sequel of infections during or following pregnancy, has received comparatively little attention, although many have considered the hazards incident to a pregnancy complicating a previously existing endocarditis. Acute malignant bacterial endocarditis, occurring more or less incidentally as a part of puerperal sepsis, has been recognized, and instances of this sort are common in any large series of cases of puerperal infection. By presenting three new cases from the Department of Pathology of the University of Michigan, this paper will endeavor to show that not only is acute malignant endocarditis a dreaded...References(1) LIBMAN E: A study of the endocardial lesions of subacute bacterial endocarditis. Am. J. M. Sc., 1912, 144:313. CrossrefGoogle Scholar(2) LIBMAN E: Characterization of various forms of endocarditis. J. A. M. A., 1923, 80:813-818. CrossrefGoogle Scholar(3) HERRICK JB: In Modern Medicine—Osler. Lea and Fiebiger, Phila., 1927, 3rd Ed. Vol. IV, p. 469. Google Scholar(4) WESTPHAL C: Endocarditis ulcerosa im Puerperium, unter dem Schein von Puerperalmanie auftretend. Archiv. f. Path. Anat. u. Physiol. (Virchow), 1861, 20:542-551. CrossrefGoogle Scholar(5) VIRCHOW R: Über die Chlorose und Endocarditis puerperalis. Beit. z. Geburt. u. Gynäk., 1872, 1: 323-359. Google Scholar(6) MATHIASPIETRUSKY EF: Allgemeines und Pathologisch-anatomisches über septische Aborte. Arch. f. Gynäk., 1923, 118, 645-653. CrossrefGoogle Scholar(7) LIBMAN E: A consideration of the prognosis in subacute bacterial endocarditis. Am. Heart Jour., 1925, 1: 25-40. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Ann Arbor, Michigan*From the Department of Pathology, University of Michigan, Ann Arbor. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1929Volume 2, Issue 9Page: 912-922KeywordsEndocarditisPregnancyPregnancy complicationsSepsis ePublished: 1 December 2008 Issue Published: 1 March 1929 PDF downloadLoading ...
Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
Authors: Waud Wr, Leopold Wr, Elliott Wl, Dykes Dj, Laster Wr, Temple Cg, Harrison Sd, Griswold Dp
Journal: Cancer Research (1990)

Ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin- 7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) was evaluated for antitumor activity against a spectrum of tumor systems in culture and in mice. NSC 370147 was cytotoxic to a variety of mouse and human cell lines at nanomolar concentrations. The compound exhibited good in vivo antitumor activity against several murine tumors (P388 and L1210 leukemia, colon 11/A and 36, mammary 16/C, and M5076 sarcoma). Activity was largely independent of route of administration but favored a prolonged treatment schedule. NSC 370147 was as active against murine leukemia sublines resistant to Adriamycin, amsacrine, vincristine, melphalan, cisplatin, methotrexate, and CI-920 (a topoisomerase II inhibitor) as against the corresponding parental lines. Only the 1-beta-D-arabinofuranosylcytosine-resistant P388 subline exhibited any cross-resistance to NSC 370147. NSC 370147 has a spectrum of activity similar to that of vincristine and, unlike vincristine, is active against multidrug-resistant cell lines. Therefore, NSC 370147 is a candidate for clinical trial because of its favorable activity compared to vincristine, its effectiveness against multidrug-resistant cells, and its retention of activity for p.o. administration.
Abstract 13133: Silencing of Angiopoietin-like Protein 3 ( <i>ANGPTL3</i> ) in IHH- Hepatocytes Results in Increased Insulin Sensitivity and Reduced Triglyceride-rich VLDL Secretion
Authors: Anna M Tikka, Pirkka-Pekka Laurila, Jarkko Soronen, Jari Metso, Christian Ehnholm, Matti Jauhiainen
Journal: Circulation (2014)

AIMS: Homozygosity of loss-of-function mutations in ANGPTL3 -gene results in familial combined hypolipidemia (FHBL2,OMIM #605019) characterized by reduction of all major plasma lipoprotein classes VLDL, LDL, HDL and low circulating free fatty acids, glucose and insulin levels. Thus complete lack of ANGPTL3 in humans not only affects lipid metabolism but also whole-body insulin and glucose balance. Our aim was to investigate the function of ANGPTL3, a hepatic secretory protein, in promoting hypolipidemia and hepatic insulin sensitivity. METHODS: We used wild type and ANGPTL3-silenced human immortalized hepatocytes (IHH) to investigate the effect of ANGPTL3-silencing on hepatic VLDL secretion and glucose uptake. RESULTS: We demonstrate that insulin downregulates hepatic secretion of ANGPTL3 and triglyceride-enriched VLDL1-type particles in a dose dependent manner. Similar effect on VLDL secretion was demonstrated with a treatment of PPAR[[Unable to Display Character: &amp;#436;]] agonist rosiglitazone. We further show that ANGPTL3-silenced cells display a more pronounced shift from the secretion of TG-enriched VLDL1-type particles to a secretion of lipid poor VLDL2-type particles during insulin stimulation. Silencing of ANGPTL3 improved hepatic glucose uptake by 20-50 % depending on the glucose and insulin concentration, resulted in a trend towards increased AKT/PKB phosphorylation upon insulin stimulation and downregulated fasting induced transcription factor PGC1α and its downstream targets. CONCLUSION: Our results indicate a similar function of both insulin and rosiglitazone regarding regulation of ANGPTL3 and VLDL secretion in hepatocytes, and suggest that insulin and PPAR[[Unable to Display Character: &amp;#436;]] might mediate some of their functions via ANGPTL3. Our results give more insight into the liver specific role of ANGPTL3 and links silencing of ANGPTL3 with Insulin sensitivity. Since humans with elevated levels of ANGPTL3 display hyperlipidemia and insulin resistance it might be beneficial to target ANGPTL3 silencing in the liver, the major site of ANGPTL3 expression, to balance lipid and glucose homeostasis and lower risk for cardiovascular diseases.
Turning 65 in Montana
Authors: Walt McDonald
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Residents and Patients: Enjoying Your Patients
Authors: G D Lundberg
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The selective proteasome inhibitor carfilzomib synergizes with the histone deacetylase (HDAC) inhibitor vorinostat in preclinical models of non-Hodgkin’s lymphoma and solid tumors
Authors: Maya Dajee, Monette Aujay, Mark Bennett, Susan Demo, Jing Jiang, Christopher Kirk, Susan Lee, Yan Lu, Guy Laidig, Jamie Shields, Congcong Sung, Han-Jie Zhou
Journal: Clinical Cancer Research (2008)

AACR Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008; Monterey, CA

A43 

Carfilzomib is a first in class tetrapeptide epoxyketone proteasome inhibitor with selectivity for the chymotrypsin-like active site. Carfilzomib has demonstrated promising safety and anti-tumor activity in Phase I and is currently in Phase II clinical studies in multiple myeloma and solid tumors (Alsin. M. et. al., Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: Abstract 411.) . Combinations of the histone deacetylase (HDAC) inhibitor vorinostat, which is approved for the treatment of cutaneous T cell lymphoma (CTCL), and proteasome inhibitors results in a synergistic increase in apoptosis in hematologic tumor cell lines. This enhanced activity corresponds to alterations in cell cycle regulation, increased oxidative stress and induction of the unfolded protein response (Marks. P. et. al.,Oncogene. 2007 Feb 26;26(9):1351-6 7). To establish the potential synergy of vorinostat and carfilzomib we initially assessed these agents in immunocompromised (BNX) mice bearing tumor xenografts of the RL (non-Hodgkin’s lymphoma) cell line. Single agent carfilzomib mediated an anti-tumor response in this model but only at its MTD (5 mg/kg). BNX mice with established tumors were treated with carfilzomib, administered on the dose schedule currently being employed in phase II trials (QDx2 repeated weekly), vorinostat, administered daily for 5 consecutive days and repeated weekly, or a combination of the two agents. We chose a sub-MTD dose of carfilzomib (3 mg/kg) in order to assess enhanced anti-tumor activity in vivo. The combination therapy induced a 48% reduction in tumor growth, as compared to vehicle treated animals, while neither single agent induced a significant anti-tumor response. Toxicity, as measured by weight loss, was similar amongst the treatment groups suggesting that the combination was well tolerated in experimental animals. We extended these findings of synergistic anti-tumor activity in our hematologic tumor model to in vitro studies with ovarian (ES-2) and renal (786-O) tumor cell lines. Synergistic cytotoxic effects, as indicated by combination index (CI) values of 0.35 and 0.76, were noted in the ES-2 and 786-O cell lines, respectively. Taken together, these data suggest that the combination vorinostat and carfilzomib is active across multiple tumor histotypes and is well tolerated and efficacious in mouse models of human tumors. Our findings support further preclinical investigation and clinical testing of this therapeutic regimen in both hematologic and solid tumor malignancies.